MOC Mobile Banner  

NEW & EXPANDED COVERAGE FOR 2017

Cancer Biotherapeutics is now part of Immuno-Oncology Summit Europe, taking place 20-24 March 2017 in London. View details at Immuno-OncologyEurope.com

Cancer Biotherapeutics: Harnessing the Immune Response and Overcoming Inhibitory FactorsTrack Divider DesignNovel Approaches for Cancer: Engineering, Optimisation and Development of Biospecifics, ADCs and Other Novel Products

View Track 1 AgendaNovel Approaches for Cancer: Engineering, Optimisation and Development of Biospecifics, ADCs and Other Novel Products  

2016 FEATURED PRESENTERS

Sergio A. QuezadaSergio A. Quezada, Ph.D.
Professorial Research Fellow, Research Haematology, University College London Cancer Institute

Martin PuleMartin Pule, Ph.D.
Senior Lecturer,
Haematology,
UCL Cancer Institute

Dario NeriDario Neri, Ph.D.
Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich

Stefan DübelStefan Dübel, Ph.D.
Managing Director and Professor, Biotechnology, Technische Universität Braunschweig

John McCaffertyJohn McCafferty, Ph.D.
CEO, IONTAS

 



ABOUT THE EVENT

Research in Cancer Biotherapeutics is progressing in leaps and bounds with rapid and exciting developments taking place with many different approaches. Cambridge Healthtech Institute, the producer of PepTalk and PEGS Protein & Antibody Engineering Summits, are responding by introducing a European event concentrating solely on this topic. Coverage focuses strongly on immunotherapy, with case studies on immune check point inhibitors, agonistic and immunomodulatory approaches, immunocytokines, chimeric antigen receptors, retargeting T cells, immunomodulatory bispecifics, oncolytic immunotherapy, and the role of dendritic cells. We also broaden the scope with presentations on targets and lead selection, fusion proteins, ADCs, and on recreating the tumour microenvironment for translational studies.

ATTENDEE TESTIMONIALS


“It was a really nice conference, in terms of the topics, the choice of speakers and the size of the meeting which lent itself well to having informal discussions during the breaks.”
Chief Science Officer, Innate Pharma

“A very informative meeting with a focus on immunotherapy, one of the most interesting fields in oncology currently. The meeting was ideal in terms of size and content. I really enjoyed the conference. It was very insightful and great quality of research was presented.”
Principal Scientist, Medicinal Chemistry, Pfizer, Inc.

View Additional Attendee Quotes

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Save the Date!
20-24 March 2017


Download Event Brochure


Premier Sponsors

Jackson Laboratory


View All Sponsors


View Media Partners



IMXE on MOC